Supreme Court: Want post-expiration royalties? Go to Congress

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Supreme Court: Want post-expiration royalties? Go to Congress

The US Supreme Court has upheld the ban on royalty payments for sales made after a patent’s expiration

Kimble v Marvel involves Stephen Kimble's invention (patent no 5,072,856) for a toy glove that allows the user to shoot foam string from the wrist. A Marvel predecessor licensed the patent for use in a Spiderman toy. The agreement had no limitation regarding the patent’s expiration. Marvel later sought a declaratory judgment ruling that it was not required to pay royalties for post-expiration sales due to the Supreme Court’s ruling in Brulotte v Thys, which bars such payments. Both the District Court and the Ninth Circuit found in favour of Marvel.

In a 6-3 decision, the Court affirmed, finding that its earlier holding expressly barred patentees from continuing to receive royalties for sales made after the patent has expired. The majority decision written by Justice Kagan held that stare decisis dictates that the Court follow the Brulotte ruling. The majority noted that while Kimble may have raised valid arguments attacking the economic underpinnings behind Brulotte, such arguments should be brought to Congress, not the court.

Similarly, the majority said that Kimble’s proposed alternative, applying the “rule of reason” analysis from antitrust law, would lead to less certainty and higher litigation costs in contrast to the bright-line Brulotte rule.

The majority also found that, despite complaints that the Brulotte prohibition restricts innovation and deal-making, there are multiple ways of drafting agreements that get around this restriction.

The dissent, written by Justice Alito and joined by Chief Justice Roberts and Justice Thomas, argued that though the majority hangs its decision on stare decisis, the underlying Brulotte decision was an example of judicial overreach that was less about interpreting the Patent Act and more about concocting policy. Alito also argued that the policy goals behind Brulotte have been “soundly refuted” and that the bar against royalties for post-expiration sales restricts parties from efficiently structuring agreements to reflect the risk of certain types of research.

Check back later in the week for in-depth analysis of this decision. For Managing IP’s coverage of the oral arguments, click here.

more from across site and SHARED ros bottom lb

More from across our site

Two partners have departed DLA Piper to join Squire Patton Boggs and Blank Rome in San Francisco and Chicago, respectively
Practitioners say a 32% rise in court fees is somewhat expected to maintain the UPC’s strong start, but some warn that SME clients could be squeezed out
Swati Sharma and Revanta Mathur at Cyril Amarchand Mangaldas explain how they overcame IP office objections to secure victory for a tyre manufacturer
Claudiu Feraru, founder of Feraru IP, discusses the benefits of a varied IP practice and why junior practitioners should learn from every case
In the ninth episode of a podcast series celebrating the tenth anniversary of IP Inclusive, we discuss IP & ME, a community focused on ethnic minority IP professionals
Firms that made strategic PTAB hires say that insider expertise is becoming more valuable in the wake of USPTO changes
Aled Richards-Jones, a litigator and qualified barrister, is the fourth partner to join the firm’s growing patent litigation team this year
An IP lawyer tasked with helping to develop Brownstein’s newly unveiled New York office is eyeing a measured approach to talent hunting
Amanda Griffiths, who will be tasked with expanding the firm’s trademark offering in New Zealand, says she hopes to offer greater flexibility to clients at her new home
News of EasyGroup failing in its trademark infringement claim against ‘Easihire’ and Amgen winning a key appeal at the UPC were also among the top talking points
Gift this article